Neutralizing anti-IL-17A antibodies, but not the isotype control, strongly inhibited the intracellular expression of BCL2A1 in Mo-DCs from LCH patients (Figures 4A, B). Here, BCL2A1 is linked to Langerhans cell histiocytosis.